MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 228 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,677,729 | -37.7% | 196,369 | -1.4% | 0.77% | -29.9% |
| Q2 2023 | $46,019,358 | -45.4% | 199,218 | -42.8% | 1.10% | -45.6% |
| Q1 2023 | $84,335,793 | -16.5% | 348,121 | 0.0% | 2.01% | -17.2% |
| Q4 2022 | $101,042,120 | +389.7% | 348,121 | +9.6% | 2.43% | +356.1% |
| Q3 2022 | $20,633,000 | -9.2% | 317,485 | 0.0% | 0.53% | -19.4% |
| Q2 2022 | $22,726,000 | -15.3% | 317,485 | +16.1% | 0.66% | -2.2% |
| Q1 2022 | $26,836,000 | +17.6% | 273,500 | +1.5% | 0.68% | +28.3% |
| Q4 2021 | $22,829,000 | +9.0% | 269,400 | +2.6% | 0.53% | +19.8% |
| Q3 2021 | $20,945,000 | -18.1% | 262,500 | 0.0% | 0.44% | -12.9% |
| Q2 2021 | $25,570,000 | -15.4% | 262,500 | +1.5% | 0.50% | -23.5% |
| Q1 2021 | $30,237,000 | +5.9% | 258,500 | +0.7% | 0.66% | +9.1% |
| Q4 2020 | $28,545,000 | -5.4% | 256,768 | +1.0% | 0.60% | -21.0% |
| Q3 2020 | $30,189,000 | +4.8% | 254,268 | 0.0% | 0.77% | -3.0% |
| Q2 2020 | $28,796,000 | +72.5% | 254,268 | +1.7% | 0.79% | +14.5% |
| Q1 2020 | $16,690,000 | -26.8% | 250,000 | -0.1% | 0.69% | -4.2% |
| Q4 2019 | $22,796,000 | -2.9% | 250,200 | -8.1% | 0.72% | -23.1% |
| Q3 2019 | $23,486,000 | -12.8% | 272,400 | +6.0% | 0.94% | -3.9% |
| Q2 2019 | $26,926,000 | -15.8% | 256,900 | +0.6% | 0.97% | -21.0% |
| Q1 2019 | $31,973,000 | +17.7% | 255,250 | +5.9% | 1.23% | -3.8% |
| Q4 2018 | $27,166,000 | -62.9% | 241,000 | -29.5% | 1.28% | -51.6% |
| Q3 2018 | $73,232,000 | -23.5% | 342,000 | -0.1% | 2.65% | -28.0% |
| Q2 2018 | $95,738,000 | +151.8% | 342,300 | +5.2% | 3.68% | +127.1% |
| Q1 2018 | $38,015,000 | +21.1% | 325,500 | -4.8% | 1.62% | +13.9% |
| Q4 2017 | $31,392,000 | +153.8% | 342,000 | +24.4% | 1.42% | +149.4% |
| Q3 2017 | $12,370,000 | +40.9% | 275,000 | -49.1% | 0.57% | +28.9% |
| Q2 2017 | $8,780,000 | +153.4% | 540,000 | +140.0% | 0.44% | +121.5% |
| Q1 2017 | $3,465,000 | +33.0% | 225,000 | +28.7% | 0.20% | +14.9% |
| Q4 2016 | $2,606,000 | +226.2% | 174,891 | +177.6% | 0.17% | +248.0% |
| Q3 2016 | $799,000 | – | 63,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HealthCor Management, L.P. | 902,601 | $100,342,000 | 3.87% |
| L1 Capital Pty Ltd | 113,464 | $12,608,000 | 2.35% |
| Avoro Capital Advisors LLC | 1,225,000 | $136,183,000 | 2.34% |
| Tao Capital Management LP | 51,396 | $5,714,000 | 1.40% |
| ARMISTICE CAPITAL, LLC | 316,000 | $35,130,000 | 1.20% |
| ACUTA CAPITAL PARTNERS, LLC | 32,500 | $3,613,000 | 0.98% |
| Capital Impact Advisors, LLC | 24,351 | $2,707,000 | 0.66% |
| Baker Brothers Advisors | 1,499,213 | $166,668,000 | 0.63% |
| Rock Springs Capital Management LP | 256,768 | $28,545,000 | 0.60% |
| SHIKIAR ASSET MANAGEMENT INC | 12,000 | $1,334,000 | 0.48% |